



ODIN is sponsored by The Novo Nordisk Foundation with 54,5 M DKK in a 3-year pilot. We have established a platform for open, **precompetitive** uni-industry collaboration **with no IP** (up to TRL 3).

All results from ODIN research are public domain.

ODIN IN BRIEF:

- Thematic foci: Biomarkers and target validation in the context of drug discovery.
- Aim: Academia and industry join forces to accelerate drug discovery and harvest competencies to collectively solve current research problems.
- Approach: Companies and researchers presented research needs/ideas and sourced input and partners from the crowd. Resulting research projects applied for funding in two call rounds. All results will be shared openly.
- Anyone can use and adapt the open results and use them for commercial purposes (with IP) – free of charge.
- Participants: Researches from three faculties at Aarhus University (NAT, TECH, and HEALTH) and more than 40 interested pharma- and biotech companies.
- We have no membership fees.**
- Funded projects: **Call round 1:** 5 projects have been started within non-alcoholic fatty liver disease, chronic kidney disease, colon cancer, cardiovascular disease, and neurological disorders.
- Call round 2:** 6 projects have been funded within chronic kidney disease, psychiatric disorders, bayesian analysis and genomics, cell penetrating peptides, Parkinson's disease, and 2D cell cultures for drug validation.
- Output examples: Project output examples include biomarkers, better models for testing lead compounds, and in-depth understanding of disease.
- In addition, the platform creates value for its participants in the form of new collaborations across the industry-university divide.